Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 222 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Long COVID Clear all
Recruiting No phase listed Observational

Long-term Impact of Infection With Novel Coronavirus (COVID-19)

NCT04362150
View directory record Official record
Conditions
COVID
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 100 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 21, 2026, 8:15 PM EDT
Withdrawn Phase 3 Interventional

REVERSE-Long COVID-19 With Baricitinib Study

NCT05858515
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome
Interventions
Baricitinib 4 MG, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
6
States / cities
San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS

NCT05633407
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome
Interventions
Efgartigimod, Placebo
Drug
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
11
States / cities
La Jolla, California • Palo Alto, California • Glenview, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 21, 2026, 8:15 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.

NCT06441955
View directory record Official record
Conditions
COVID-19, Long Haul
Interventions
Ritonavir-Boosted Nirmatrelvir (Paxlovid), Physiological Evaluation, Moderna COVID-19 Vaccine, Biopsychological, Behavioral (e.g., Psychotherapy, Lifestyle Counseling), Genetic (including gene transfer, stem cell and recombinant DNA), Multidisciplinary approach
Drug · Diagnostic Test · Biological + 3 more
Lead sponsor
Well- Konnect Healthcare Services and Research Firm
Network
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 21, 2026, 8:15 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)

NCT05855369
View directory record Official record
Conditions
Smell Dysfunction, Olfactory Disorder, Long COVID
Interventions
Trigeminal Nerve Stimulation (TNS), Active Smell Training (ST), Placebo Smell Training (PBO)
Device · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 21, 2026, 8:15 PM EDT
Active, not recruiting No phase listed Observational

A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)

NCT06189053
View directory record Official record
Conditions
Myocarditis
Interventions
Not listed
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 21, 2026, 8:15 PM EDT
Terminated Phase 3 Interventional Results available

Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial

NCT05946551
View directory record Official record
Conditions
COVID-19
Interventions
Cetirizine, Famotidine, Cetirizine Placebo, Famotidine Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 21, 2026, 8:15 PM EDT
Not listed Not applicable Interventional

Amygdala Insula Retraining in the Management of Long COVID Symptoms

NCT05851846
View directory record Official record
Conditions
Long COVID
Interventions
Amygdala insula retraining
Behavioral
Lead sponsor
Miami VA Healthcare System
Federal
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Fort Lauderdale, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 21, 2026, 8:15 PM EDT
Recruiting Not applicable Interventional

The Long COVID-19 Wearable Device Study

NCT05741112
View directory record Official record
Conditions
Long COVID, Postural Orthostatic Tachycardia Syndrome, Dysautonomia, Myalgic Encephalomyelitis, Chronic Fatigue Syndrome, Long Covid19
Interventions
Wearable device
Device
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
100,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 21, 2026, 8:15 PM EDT
Not listed No phase listed Observational

Effect of Apollo Wearable on Long COVID-19 Symptoms.

NCT06097442
View directory record Official record
Conditions
Post-acute Sequelae of SARS-COV-2 Infection
Interventions
Not listed
Lead sponsor
The Board of Medicine
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 21, 2026, 8:15 PM EDT
Completed Not applicable Interventional

Multimodal Investigation of Post COVID-19 in Females

NCT05225220
View directory record Official record
Conditions
Post COVID-19, Cognitive Dysfunction
Interventions
Parasym Device (of Parasym Ltd, UK) using Transcutaneous Vagus Nerve Stimulation (t-VNS)
Device
Lead sponsor
Casa Colina Hospital and Centers for Healthcare
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 21, 2026, 8:15 PM EDT
Enrolling by invitation Not applicable Interventional

Cognitive Rehabilitation Therapy for COVID-19

NCT06086379
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome
Interventions
Compensatory Cognitive Training for COVID-19, Holistic Cognitive Education
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 21, 2026, 8:15 PM EDT
Enrolling by invitation No phase listed Observational

Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions

NCT06257420
View directory record Official record
Conditions
Myalgic Encephalomyelitis, Long-COVID
Interventions
Rapamycin
Drug
Lead sponsor
Simmaron Research Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Palo Alto, California • Rochester, Minnesota • Incline Village, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 21, 2026, 8:15 PM EDT
Active, not recruiting Phase 2 Interventional

Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial

NCT05690503
View directory record Official record
Conditions
Post-acute Sequelae of COVID-19, Depressive Symptoms, Cognitive Dysfunction
Interventions
CI-581a, CI-581b
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 21, 2026, 8:15 PM EDT
Completed Not applicable Interventional Results available

RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms

NCT05965739
View directory record Official record
Conditions
Long COVID, Long Covid19, Long Covid-19
Interventions
BrainHQ/Active Comparator Activity, BrainHQ, PASC CoRE, tDCS-active, tDCS-sham
Other · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 21, 2026, 8:15 PM EDT
Recruiting Phase 2 Interventional

Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS

NCT07189936
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome, Postural Tachycardia Syndrome (POTS), SARS CoV 2 Infection, Long COVID19
Interventions
To Measure levels of circulating monocyte/ T cell doublets at Baseline, To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment, To measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment, To Measure Splanchnic venous capacitance after 28 days of Treatment with 2HOBA, To Measure Splanchnic venous capacitance after 28 days of Treatment with Placebo, To Measure Orthostatic Tachycardia after 28 days of Treatment with 2HOBA, To Measure Orthostatic Tachycardia after 28 days of Treatment with Placebo
Drug · Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 21, 2026, 8:15 PM EDT
Withdrawn Not applicable Interventional

TDCS-potentiated Generalization of Cognitive Training in the Rehabilitation of Long COVID Symptoms

NCT05589272
View directory record Official record
Conditions
Post-acute Sequelae SARS-CoV-2 Infection (PASC)
Interventions
Active tDCS, Sham tDCS
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 21, 2026, 8:15 PM EDT
Completed Not applicable Interventional Results available

Developing an Integrative, Recovery-Based, Post-Acute COVID-19 Syndrome (PACS) Psychotherapeutic Intervention

NCT05453201
View directory record Official record
Conditions
Long COVID
Interventions
Long COVID Coping and Recovery (LCCR) Intervention
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 21, 2026, 8:15 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

NCT06920628
View directory record Official record
Conditions
Long COVID, Post Acute Sequelae of COVID-19
Interventions
11C-PS13
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 21, 2026, 8:15 PM EDT
Withdrawn Phase 2 Interventional

A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid

NCT06234462
View directory record Official record
Conditions
Long COVID, Post-Acute COVID-19 Syndrome
Interventions
Amantadine, Physical, Occupational, Speech Therapy, Provider Counseling, Medications for symptoms management
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
20 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 21, 2026, 8:15 PM EDT
Recruiting Not applicable Interventional

Long COVID Brain Fog: Cognitive Rehabilitation Trial

NCT06095297
View directory record Official record
Conditions
Long COVID, Brain Fog, Cognitive Impairment, Cognitive Dysfunction, Post-Acute COVID-19 Syndrome
Interventions
Processing Speed Training, In-lab Instrumental Activities of Daily Living Training, In-lab Brain Health Training, Transfer Package, Follow Up Phone Calls, Vocational Rehabilitation, Peer Mentoring, Reaction Time Training, Trans-auricular Vagus Nerve Stimulation: High Intensity, Trans-auricular Vagus Nerve Stimulation: Low Intensity
Behavioral · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 21, 2026, 8:15 PM EDT
Active, not recruiting No phase listed Observational

Post Acute Sequelae of COVID-19

NCT04964115
View directory record Official record
Conditions
Covid19, Sars-CoV-2 Infection, Dyspnea Caused by 2019-nCoV, COVID-19 Acute Respiratory Distress Syndrome, Pulmonary Fibrosis
Interventions
Cohort study
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 21, 2026, 8:15 PM EDT
Recruiting Phase 2 Interventional

Antiviral Clinical Trial for Long Covid-19

NCT06511063
View directory record Official record
Conditions
Long Covid
Interventions
tenofovir disoproxil/emtricitabine, Selzentry, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 21, 2026, 8:15 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID

NCT06974084
View directory record Official record
Conditions
Long COVID
Interventions
Maraviroc (MVC), Atorvastatin, 10mg, 20mg, 40mg, Placebo, Maraviroc, Placebo, Atorvastatin
Drug
Lead sponsor
HealthBio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 21, 2026, 8:15 PM EDT